StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Deferoxamin

Deferoxamine

HCID 2973
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
70-51-9
Standard-SMILES
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
Summenformel
C25H48N6O8
Durchschnittliche Molmasse
560,7 g/mol
Monoisotopische Masse
560,3533625

Überblick

Desferrioxamine B is an acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N1-(5-aminopentyl)-N1-hydroxy-N4-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator. It has a role as a ferroptosis inhibitor, a siderophore, an iron chelator and a bacterial metabolite. It is a conjugate base of a desferrioxamine B(1+). It is a conjugate acid of a desferrioxamine B(3-).

Namen und Bezeichner

Bevorzugter Name
Deferoxamine
IUPAC
N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide
Lokaler Name
Deferoxamin
Englischer Name
Deferoxamine
Summenformel
C25H48N6O8
Molmasse
560.69

Namen und Synonyme

deferoxamine70-51-9Desferrioxamine BDESFERRIOXAMINEDeferrioxamineDeferoxamine BDeferrioxamine BDeferoxaminDeferoxaminumDesferinDFOMDesferan
Weitere Namen anzeigen
DESFEROXAMINEtaoneentaoneba33112ba-29837ba-33112
DesferexDesferralDesferrinN-Benzoylferrioxamine BDeferoxaminaDFOANSC-527604Ferrioxamine B, N-benzoyl-

Datenbank-Bezeichner

CAS
70-51-9
PubChem CID
2973
DTXSID
DTXSID7022887
ChEMBL
CHEMBL556
ChEBI
CHEBI:4356
UNII
J06Y7MXW4D
EC Number
200-738-5
Nikkaji
J10.199K

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-2,1
Polarare Oberfläche (TPSA)
206 Ų
H-Brücken-Donoren
6
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
23
Schwere Atome
39
Formalladung
0
Komplexität
739

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LipidsFatty Acyls [FA] -> Fatty amides [FA08] -> N-acyl amines [FA0802]
LogP · 2 Einträge

-2.2

-1.52

Solubility9.90e-02 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Chelating Agents; Iron Chelating Agents

Antidotes and other substances used in poisonings > Specific

Melting Point · 3 Einträge

MP: 138-140 °C /MONOHYDRATE/; 172-175 °C /HYDROCHLORIDE/; 148-149 °C /METHANESULFONATE/

MP: 180-182 °C /N-ACETYL DERIV/

138 - 140 °C

Physical DescriptionSolid
Stability/Shelf LifeRECONSTITUTED SOLN ARE STABLE FOR 2 WK @ ROOM TEMP /MESYLATE/

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (97.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 69 reports by companies from 3 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory InformationStatus: Active Update: 07-06-2016 https://echa.europa.eu/registration-dossier/-/registered-dossier/17782
Hazard Classes and CategoriesAcute Tox. 4 (97.1%)

Toxikologische Informationen

InteractionsTHE CONCOMITANT ORAL ADMINISTRATION OF ASCORBIC ACID (0.5 TO 1 G TWICE DAILY) SEEMS TO IMPROVE THE CHELATING ACTION OF DEFEROXAMINE IN HEMOCHROMATOSIS, PARTICULARLY IF THERE IS A VITAMIN C DEFICIENCY.
Hepatotoxicity · 1 Eintrag

In large clinical trials, elevations in serum aminotransferase levels were rare in patients receiving deferoxamine and instances of acute, clinically apparent liver injury were not reported. Patients with transfusion related iron overload often have concurrent chronic hepatitis B or C, and elevations of serum aminotransferase levels during chelation therapy may be due to natural fluctuations in the underlying chronic liver disease activity. Nevertheless, elevations in serum aminotransferase levels and “hepatic dysfunction” are listed as potential adverse events in product labels for deferoxamine. After an early report of hepatitis occurring in patient on hemodialysis receiving deferoxamine to reduce aluminum levels, there have been no further published instances of clinically apparent liver injury that have been convincingly linked to deferoxamine therapy.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

V03AC01

V - Various

QV - Various

V03AC01

Protein BindingLess than 10% bound to serum proteins <i>in vitro</i>.
Pharmacodynamics · 1 Eintrag

Deferoxamine, otherwise known as desferrioxamine or desferal, is a chelating agent used to remove excess iron or aluminum from the body. It acts by binding free iron or aluminum in the bloodstream and enhancing its elimination in the urine. By removing excess iron or aluminum, the agent reduces the damage done to various organs and tissues, such as the liver.

Mechanism of Action · 3 Einträge

Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum.

DEFEROXAMINE HAS...REMARKABLY HIGH AFFINITY FOR FERRIC IRON... IT...COMPETES FOR IRON OF FERRITIN & HEMOSIDERIN, BUT IT REMOVES ONLY SMALL AMOUNT OF IRON OF TRANSFERRIN. ... GIVEN ORALLY, DEFEROXAMINE BINDS IRON IN LUMEN OF BOWEL & RENDERS THE METAL NONABSORBABLE.

IT READILY COMPLEXES WITH FERRIC ION TO FORM FERRIOXAMINE, COLORED, STABLE, WATER-SOL CHELATE; IT ALSO HAS LIMITED AFFINITY FOR FERROUS ION. /MESYLATE/

Biological Half-LifeBiphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.
Metabolism/Metabolites · 2 Einträge

Deferoxamine is mainly metabolised in the plasma and hepatic metabolism is minimal. A number of metabolites have been isolated but not characterised. Some metabolites of deferoxamine, most notably the product of oxidative deamination, also chelate iron, and thus the antidotal effect of the drug appears unaffected by hepatic metabolism.

Zugehörige Reaktionen

16
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 24973
HRID 24973als Edukt
Reaktionsgleichung von HRID 24974
HRID 24974als Edukt
Reaktionsgleichung von HRID 24975
HRID 24975als Edukt
Reaktionsgleichung von HRID 979002
HRID 979002als Edukt
Reaktionsgleichung von HRID 1061480
HRID 1061480als Edukt
Reaktionsgleichung von HRID 1376572
HRID 1376572als Produktals Edukt
Reaktionsgleichung von HRID 1376573
HRID 1376573als Produktals Edukt
Reaktionsgleichung von HRID 1376574
HRID 1376574als Produktals Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Collision Cross Section
228.86 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Other Experimental Properties · 4 Einträge

CRYSTALS FROM DIL ALC /MONOHYDRATE/

CRYSTALS FROM SLIGHTLY ACIDIC METHANOL /HYDROCHLORIDE/

CRYSTALS FROM DIL ALC /METHANESULFONATE/

CRYSTALS FROM N-PROPANOL /N-ACETYL DERIV/

Physikochemische Eigenschaften

Schmelzpunkt
139 °C · 139°C
Siedepunkt
627.9 °C · 627.9°C (rough estimate)
Dichte
1.2216 · 1.2216 (rough estimate)
Brechungsindex
1.554 · 1.5540 (estimate)
storage temp.
-20 °C · -20°C
Aggregatzustand
Solid
pka
9.08 · 9.08±0.50(Predicted)
Farbe
White to off-white
Major Application
pharmaceutical
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
SMILES
C(=O)(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C
EPA chemische Informationen
Deferoxamine (70-51-9)
Adverse Effects · 1 Eintrag

Chronic deferoxamine therapy can lead to sensorineural hearing loss and retinopathy. Though the mechanism of ocular injury is not well understood, it appears to partially occur due to damage to the retinal pigment epithelium, which can lead to decreased visual acuity, visual field defects, and color vision defects. Hearing and vision loss can be reversible if the patient discontinues the drug early in the course. Growth retardation can also occur in children receiving deferoxamine treatment, and clinicians should monitor patients for appropriate growth velocity over time.

Toxicity SummaryPatients tolerate deferoxamine well, and there is no specific antidote for the medication. The precautions and dose reductions are described elsewhere in this paper.
Human Toxicity Excerpts · 4 Einträge

PAIN & INDURATION MAY OCCUR @ SITE OF IM INJECTION. OTHER UNTOWARD EFFECTS INCL ERYTHEMA, FLUSHING, DIARRHEA, BLURRING OF VISION, ABDOMINAL DISCOMFORT, MUSCULAR SPASMS IN LEGS, ITCHING, TACHYCARDIA, & FEVER. IN LONG TERM THERAPY, VARIOUS ALLERGIC REACTIONS, INCL ANAPHYLAXIS, HAVE BEEN REPORTED. /MESYLATE/

REACTIONS HAVE INCLUDED HYPOTENSION, PROBABLY DUE TO HISTAMINE RELEASE (ESP DURING IV ADMIN), SKIN RASHES, & GI IRRITATION. OCCASIONAL CASES OF CATARACT FORMATION IN MAN HAVE BEEN REPORTED...

A WOMAN WITH BETA-THALASSAEMIA INTERMEDIA, AND IRON OVERLOAD FOLLOWING MANY YEAR'S THE COURSE OF THIS TREATMENT SHE DEVELOPED TINNITUS, WHICH WAS CONSIDERED TO BE A RARE COMPLICATION OF THE USE OF THIS CHELATING AGENT.

DESFERRIOXAMINE WAS GIVEN INTRAVENOUSLY, AT HIGHER DOSES THAN PREVIOUSLY REPORTED, TO COUNTER THE EFFECTS OF TRANSFUSION-INDUCED IRON OVERLOAD IN FOUR PATIENTS WITH BETA THALASSAEMIA MAJOR. IN TWO OF THEM RETINAL ABNORMALITIES DEVELOPED, PRESENTING WITH NIGHT BLINDNESS AND FIELD DEFECTS, WHICH IMPROVED ON WITHDRAWAL OF THE DRUG.

Drug Induced Liver Injury · 6 Einträge

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

deferoxamine

Desferal®

Chelating agents

Not Applicable

no-DILI-concern

Non-Human Toxicity Excerpts · 5 Einträge

DOGS TOLERATE SINGLE IV DOSES UP TO 100 MG/KG WITH SIGNS SUGGESTING TRANSIENT HYPOTENSION.

...IT HAS PRODUCED OPACITIES IN CRYSTALLINE LENS IN DOGS, CATS, & RATS WHEN GIVEN BY DAILY SC INJECTION FOR LONG PERIODS @ DOSAGES SO LARGE THAT THEY PRODUCE SEVERE GASTROENTERITIS.

INJECTION OF 28.5% SOLN SUBCONJUNCTIVALLY HAS CAUSED SLIGHT CHEMOSIS & HYPEREMIA. ... INJECTION OF 50 MG SUBCONJUNCTIVALLY WAS TOLERATED BY EYES OF MONKEYS...

...50 MG INJECTED SUBCONJUNCTIVALLY IN RABBITS EVERY 1-3 DAYS FOR SEVERAL MO WAS TOLERATED...BUT 200 MG SUBCONJUNCTIVALLY IN RABBITS CAUSED REDN IN RESPONSE OF PUPIL TO LIGHT, CONGESTION OF UVEA, & EXUDATIVE DETACHMENT OF CHOROID & RETINA...

INTRAVITREAL INJECTIONS OF 5 MG DEFEROXAMINE IN RABBITS PROVED VERY TOXIC, CAUSING WIDESPREAD HEMORRHAGIC NECROSIS, PARTICULARLY AFFECTING RODS & CONES OF RETINA & EXTINGUISHING ELECTRORETINOGRAM.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 3
Toxizität
LD50 oral in mouse: 1340mg/kg
Speicherklasse
11 - Combustible Solids
Giftige Stoffe Daten
70-51-9(Hazardous Substances Data)

DEFEROXAMINE IS METABOLIZED PRINCIPALLY BY PLASMA ENZYMES, ALTHOUGH THE PATHWAYS HAVE NOT YET BEEN DEFINED.

FDA Pharmacological Classification · 5 Einträge

J06Y7MXW4D

DEFEROXAMINE

Mechanisms of Action [MoA] - Iron Chelating Activity

Established Pharmacologic Class [EPC] - Iron Chelator

Deferoxamine is an Iron Chelator. The mechanism of action of deferoxamine is as an Iron Chelating Activity.

MeSH Pharmacological ClassificationLow-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
Absorption, Distribution and Excretion · 3 Einträge

Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.

Deferoxamine mesylate is metabolized principally by plasma enzymes, but the pathways have not yet been defined. Some is also excreted in the feces via the bile.

THE DRUG IS...READILY EXCRETED IN URINE.

Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 2 Einträge

MEDICATION

Use (kg; approx.) in Germany (2009): >100

Methods of ManufacturingNATURAL PRODUCT FORMING IRON COMPLEXES, ISOLATED FROM STREPTOMYCES PILOSUS, ETTLINGER ET AL, ISOLATION: BICKEL ET AL, HELV CHIM ACTA 43, 2118 (1960). PREPN FROM FERRIOXAMINE B & STRUCTURE: BICKEL ET AL, HELV CHIM ACTA 43, 2129 (1960).
Formulations/Preparations · 2 Einträge

STERILE DEFEROXAMINE MESYLATE, USP (DESFERAL MESYLATE), IS AVAILABLE IN AMPULES CONTAINING 500 MG OF THE DRUG. /MESYLATE/

DESFERAL (CIBA). INJECTION: LYOPHILIZED POWDER (FOR SOLN) 500 MG.

General Manufacturing Information · 1 Eintrag

THE IRON-CHELATING AGENT DESFERROXAMINE INHIBITED BOTH THE BASELINE AND IRON-STIMULATED AUTOXIDATION OF DOPAMINE OR NOREPINEPHRINE. DESFERROXAMINE APPEARS TO BE A USEFUL TOOL THAT MAY BE ADDED TO SOLUTIONS CONTAINING CATECHOLAMINES TO PREVENT THEIR DEGRADATION.

Anwendungen · 2 Einträge

BeschreibungDeferoxamine was introduced in the 1960s for chelation of iron. It is synthesized by removing a central iron molecule from ferrioxamine B, a compound obtained from the microorganism Streptomyces pilosus. Deferoxamine binds to iron from ferritin and forms ferrioxamine, a very stable and water-soluble chelate with a characteristic reddish color.

VerwendenDeferoxamine is used for the treatment of both acute iron intoxication and chronic iron overload due to transfusiondependent anemias. It has also been used in trials for malaria treatment and for aluminum chelation in hemodialysis patients. Studies of a rat model of intracerebral hemorrhage have noted that deferoxamine treatment reduced oxidative stress from iron release, indicating a possible role in preventing damage associated with hemorrhagic strokes.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

DicyclohexylcarbodiimidNatriumcyantrihydroboratO-BenzylhydroxylaminhydrochloridBernsteinsureanhydridPalladiumdihydroxidEssigsäureanhydridAluminium-nickel6-Dimethylaminopurin4-[(5-{[(benzyloxy)carbonyl]amino}pentyl)(hydroxy)amino]-4-oxobutanoic acidButanoic acid, 4-[(4-cyanobutyl)(phenylmethoxy)amino]-4-oxo-benzyl N-[5-(N-hydroxy-3-{[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]carbamoyl}propanamido)pentyl]carbamateButanediamide, N'-[5-[[4-[[5-[acetyl(phenylmethoxy)amino]pentyl]amino]-1,4-dioxobutyl](phenylmethoxy)amino]pentyl]-N-(4-cyanobutyl)-N-(phenylmethoxy)- (9CI)(5-Aminopentyl)(phenylmethoxy)carbamic acid tert-butyl esterbenzyl 5-(3,6-dioxomorpholino)pentylcarbamateBenzyl (5-(hydroxyaMino)pentyl)carbaMate